Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients
Generalized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pathogenesis. Spesolimab is a novel systemic biologic therapy that selectively inhibits interleukin-36. It was recently approved by Health Canada and the US FDA for the treatment of GPP flares in adults. Results from phase 1 and 2 studies have been promising. Herein, we review the efficacy and safety of spesolimab for the treatment of GPP flares, as demonstrated in clinical trials.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Skin therapy letter - 29(2024), 1 vom: 01. Jan., Seite 1-4 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bukhari, Tuba [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 29.01.2024 Date Revised 29.01.2024 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM367619490 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367619490 | ||
| 003 | DE-627 | ||
| 005 | 20240129232149.0 | ||
| 007 | tu | ||
| 008 | 240126s2024 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1274.xml |
| 035 | |a (DE-627)NLM367619490 | ||
| 035 | |a (NLM)38271532 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bukhari, Tuba |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 29.01.2024 | ||
| 500 | |a Date Revised 29.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Generalized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pathogenesis. Spesolimab is a novel systemic biologic therapy that selectively inhibits interleukin-36. It was recently approved by Health Canada and the US FDA for the treatment of GPP flares in adults. Results from phase 1 and 2 studies have been promising. Herein, we review the efficacy and safety of spesolimab for the treatment of GPP flares, as demonstrated in clinical trials | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a biologics | |
| 650 | 4 | |a clinical trial | |
| 650 | 4 | |a generalized pustular psoriasis | |
| 650 | 4 | |a interleukin-36 | |
| 650 | 4 | |a spesolimab | |
| 650 | 7 | |a spesolimab |2 NLM | |
| 650 | 7 | |a 5IB2J79MCX |2 NLM | |
| 650 | 7 | |a Interleukin Inhibitors |2 NLM | |
| 650 | 7 | |a Interleukins |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a IL36RN protein, human |2 NLM | |
| 700 | 1 | |a Markovina, Mariya |e verfasserin |4 aut | |
| 700 | 1 | |a Abduelmula, Abrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Rankin, Brian D |e verfasserin |4 aut | |
| 700 | 1 | |a Vender, Ronald |e verfasserin |4 aut | |
| 700 | 1 | |a Yeung, Jensen |e verfasserin |4 aut | |
| 700 | 1 | |a Devani, Alim R |e verfasserin |4 aut | |
| 700 | 1 | |a Prajapati, Vimal H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Skin therapy letter |d 1998 |g 29(2024), 1 vom: 01. Jan., Seite 1-4 |w (DE-627)NLM098266810 |x 1201-5989 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2024 |g number:1 |g day:01 |g month:01 |g pages:1-4 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2024 |e 1 |b 01 |c 01 |h 1-4 | ||